Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 33

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 1
Chunk 33
---
,748,000 in the nine months ended July 31, 2024. The decrease in general and administrative expenses was primarily due
to a decrease in investor and public relations expense of approximately $478,000, a decrease in director stock-based compensation of
approximately $280,000, a decrease in employee stock-based compensation of approximately $68,000, and a decrease in consulting fees of
approximately $58,000, offset by an increase in patent-related costs of approximately $67,000.

Interest
Income

Interest
income decreased by approximately $364,000 to approximately $519,000 in the nine months ended July 31, 2025, from approximately $883,000
in the nine months ended July 31, 2024, primarily due to a decrease in the amount of short-term investments held and a decrease in interest
rates.

Net
Loss Attributable to Noncontrolling Interest

The
net loss attributable to noncontrolling interest, representing Wistar’s ownership interest in Certainty’s net loss, decreased
by approximately $40,000 to approximately $74,000 in the nine months ended July 31, 2025 from approximately $114,000 in the nine months
ended July 31, 2024, as Certainty’s net loss decreased.

LIQUIDITY
AND CAPITAL RESOURCES

Our
primary sources of liquidity are cash, cash equivalents and short-term investments.

Based
on currently available information as of September 10, 2025, we believe that our existing cash, cash equivalents and short-term investments
will be sufficient to fund our activities for at least the next twelve months. The Company had approximately $16,029,000 of cash, cash
equivalents and short-term investments at July 31, 2025 compared to approximately $19,924,000 at October 31, 2024 which is a reduction
of approximately $3,895,000 for the nine months ended July 31, 2025. Therefore, the Company believes that it has sufficient cash, cash
equivalents and short-term investments to operate its business, as currently contemplated, for significantly longer than 12 months from
the date of this Report. We have implemented a business model that conserves funds by collaborating with third parties to develop our
technologies. During the nine months ended July 31, 2025, we raised approximately $1,924,000, net of expenses, through an at-the-market
equity offering